Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

STAT+: RevMed’s pancreatic cancer drug nears European approval

Дата публикации: 16-10-2026 13:38:22

Following a green light from the FDA, European regulators have now recommended the approval of Revolution Medicines' Rasonque for pancreatic cancer.

Основное содержимое страницы с новостью.

Merck and Moderna plot cancer vaccine expansion, China’s boom reshapes global venture investing, and more biotech news
Revolution Medicines

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We’re leaving room for popcorn and intrigue tonight: The new A24 documentary, “You Can See Everything,” hits theaters today.

I remember back at the American Association for Clinical Chemistry meeting in 2016, a skeptical pathologist told me in advance of a purported Theranos data unveil: 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribersUnlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. Biotech Correspondent

    Meghana Keshavan covers biotech and contributes to The Readout newsletter.

  2. Europe Correspondent

    Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1 Europa apuesta por el fármaco que duplica la supervivencia en pacientes con cáncer de páncreas 08.1916-10-2026
2STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer012.0715-10-2026
3FDA approves groundbreaking new pancreatic cancer drug07.7726-08-2026
4Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer014.5622-07-2026
5FDA approves landmark pancreatic cancer drug that's shown to improve survival07.926-08-2026
6Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer015.8102-07-2026
7دواء تجريبي يعزز فرص النجاة لدى مرضى سرطان البنكرياس5731-05-2026
8New targeted therapy shows promising early results in advanced pancreatic cancer2705-07-2026
9New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer5702-07-2026
10Cancer du pancréas : une première européenne au CHU Grenoble Alpes0512-05-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 6.85. Источник: www.statnews.com.